ArticleJournal of virology2004
By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber/W editing and its own expression.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Woodchuck and deer Hepatitis Delta-like agents show distinct innate immune activation and IFN-resistance compared to human Hepatitis D Virus.Scientific reports · 2026Article
- Differential impact of hepatitis delta virus replication and expression of viral antigens on the cellular kinome profile.Cell communication and signaling : CCS · 2025Article
- Diversity and evolution of viroids and viroid-like agents with circular RNA genomes revealed by metatranscriptome mining.Nucleic acids research · 2025Article
- Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients.Biomedicines · 2025Article
- Review
- HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression.Viruses · 2024Article
- Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly.JHEP reports : innovation in hepatology · 2024Article
- Review
- Hepatitis Delta Infection: A Clinical Review.Seminars in liver disease · 2023Review
- Diagnosis of HDV: From virology to non-invasive markers of fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2023Review
- Host-mediated RNA editing in viruses.Biology direct · 2023Review
- Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.Alimentary pharmacology & therapeutics · 2022Review
- Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.Frontiers in microbiology · 2022Review
- Epitranscriptomic marks: Emerging modulators of RNA virus gene expression.Wiley interdisciplinary reviews. RNA · 2020Review
- Structural Pattern Differences in Unbranched Rod-like RNA of Hepatitis Delta Virus affect RNA Editing.Viruses · 2019Article
- HBV/HDV Coinfection: A Challenge for Therapeutics.Clinics in liver disease · 2019Review
- Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation.Nature communications · 2019Article
- The Hepatitis Delta Virus accumulation requires paraspeckle components and affects NEAT1 level and PSP1 localization.Scientific reports · 2018Article
- Life cycle and pathogenesis of hepatitis D virus: A review.World journal of hepatology · 2013Review
- Arginine-rich motifs are not required for hepatitis delta virus RNA binding activity of the hepatitis delta antigen.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hepatitis delta virus (HDV) expresses two essential proteins with distinct functions. The small hepatitis delta antigen (HDAg-S) is expressed throughout replication and is needed to promote that process. The large form (HDAg-L) is farnesylated, is expressed only at later times via RNA editing of the amber/W site, and is required for virion assembly. When HDAg-L is artificially expressed at the onset of replication, it strongly inhibits replication. However, there is controversy concerning whether HDAg-L expressed naturally at later times as a consequence of editing and replication can similarly inhibit replication. Here, by stabilizing the predicted secondary structure downstream from the amber/W site, a replication-competent HDV mutant that exhibited levels of editing higher than those of the wild type was created. This mutant expressed elevated levels of HDAg-L early during replication, and at later times, its replication aborted prematurely. No further increase in amber/W editing was observed following the cessation of replication, indicating that editing was coupled to replication. A mutation in HDAg-L and a farnesyl transferase inhibitor were both used to abolish the ability of HDAg-L to inhibit replication. Such treatments rescued the replication defect of the overediting mutant, and even higher levels of amber/W editing resulted. It was concluded that when expressed naturally during replication, HDAg-L is able to inhibit replication and thereby inhibit amber/W editing and its own synthesis. In addition, the structure adjacent to the amber/W site is suboptimal for editing, and this creates a window of time in which replication can occur in the absence of HDAg-L.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.